Review of Burden, Clinical Definitions, and Management of COVID-19 Cases
- PMID: 32618260
- PMCID: PMC7410412
- DOI: 10.4269/ajtmh.20-0564
Review of Burden, Clinical Definitions, and Management of COVID-19 Cases
Abstract
Our understanding of SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19), its clinical manifestations, and treatment options continues to evolve at an unparalleled pace. This review sought to summarize the key literature regarding transmission, case definitions, clinical management, and the burden of COVID-19. Our review of the literature showed that SARS-CoV-2 was mainly transmitted via inhalation of respiratory droplets containing the virus and had a mean incubation period of 4-6 days. The commonly reported symptoms were fever (75.3% ± 18.7%) and cough (62.6% ± 17.7%) across the spectrum of clinical disease-mild, moderate, severe, and critical, but with the disease phenotype varying with severity. Categorization of these cases for home care or hospital management needs to be defined, with risk stratification accounting for the age of the patient and the presence of underlying comorbidities. The case definitions varied among countries, which could have contributed to the differences in the case fatality rates among affected countries. The severity and risk of death due to COVID-19 was associated with age and underlying comorbidities. Asymptomatic cases, which constitute 40-80% of COVID-19 cases are a considerable threat to control efforts. The presence of fever and cough may be sufficient to warrant COVID-19 testing, but using these symptoms in isolation will miss a proportion of cases. A clear definition of a COVID-19 case is essential for the management, treatment, and tracking of clinical illness, and to inform the quarantine measures and social distancing that can help control the spread of SARS-CoV-2.
Conflict of interest statement
Financial support: This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (APP1161076 to J. S. R.). Burnet Institute received funding from the NHMRC Independent Research Institutes Infrastructure Support Scheme and the Victorian State Government Operational Infrastructure Support Scheme.
Disclosure: ZiP Diagnostics is commercializing a COVID-19 point-of-care test. C. A. N., D. S., and J. S. R. have part-time employment at ZiP.
Figures
References
-
- Lee N, et al. 2003. A major outbreak of severe acute respiratory syndrome in Hong Kong. New Engl J Med 348: 1986–1994. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
